MA53270A - Diazabicyclooctanones en tant qu'inhibiteurs de bêta-lactamases à sérine - Google Patents
Diazabicyclooctanones en tant qu'inhibiteurs de bêta-lactamases à sérineInfo
- Publication number
- MA53270A MA53270A MA053270A MA53270A MA53270A MA 53270 A MA53270 A MA 53270A MA 053270 A MA053270 A MA 053270A MA 53270 A MA53270 A MA 53270A MA 53270 A MA53270 A MA 53270A
- Authority
- MA
- Morocco
- Prior art keywords
- diazabicyclooctanones
- serin
- beta
- lactamase inhibitors
- lactamase
- Prior art date
Links
- 239000003781 beta lactamase inhibitor Substances 0.000 title 1
- 229940126813 beta-lactamase inhibitor Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18213635.8A EP3670512A1 (fr) | 2018-12-18 | 2018-12-18 | Diazabicyclooctanones comme inhibiteurs de sérine beta-lactamases |
PCT/EP2019/071370 WO2020030761A1 (fr) | 2018-08-09 | 2019-08-08 | Diazabicyclooctanones en tant qu'inhibiteurs de bêta-lactamases à sérine |
Publications (2)
Publication Number | Publication Date |
---|---|
MA53270A true MA53270A (fr) | 2022-04-06 |
MA53270B1 MA53270B1 (fr) | 2023-11-30 |
Family
ID=64745939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA53270A MA53270B1 (fr) | 2018-12-18 | 2019-08-08 | Diazabicyclooctanones comme inhibiteurs de sérine beta-lactamases |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP3670512A1 (fr) |
EA (1) | EA202190444A1 (fr) |
MA (1) | MA53270B1 (fr) |
PT (1) | PT3833665T (fr) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2533826T3 (es) * | 2008-01-18 | 2015-04-15 | Merck Sharp & Dohme Corp. | Inhibidores de beta-lactamasa |
CN103649088B (zh) * | 2011-08-30 | 2016-05-11 | 沃克哈特有限公司 | 1, 6- 二氮杂双环[3, 2, 1]辛- 7- 酮衍生物及其在治疗细菌感染中的用途 |
GB201310542D0 (en) | 2013-06-13 | 2013-07-31 | Antabio Sas | Compounds |
GB2533136A (en) | 2014-12-11 | 2016-06-15 | Antabio Sas | Compounds |
CN107501265B (zh) * | 2017-10-09 | 2019-05-28 | 台州职业技术学院 | 一种7-氧代-二氮杂二环[3,2,1]辛烷衍生化合物及其制备方法和应用 |
-
2018
- 2018-12-18 EP EP18213635.8A patent/EP3670512A1/fr not_active Ceased
-
2019
- 2019-08-08 MA MA53270A patent/MA53270B1/fr unknown
- 2019-08-08 PT PT197558505T patent/PT3833665T/pt unknown
- 2019-08-08 EA EA202190444A patent/EA202190444A1/ru unknown
Also Published As
Publication number | Publication date |
---|---|
EP3670512A1 (fr) | 2020-06-24 |
PT3833665T (pt) | 2023-10-19 |
MA53270B1 (fr) | 2023-11-30 |
EA202190444A1 (ru) | 2021-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA54547A (fr) | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a | |
MA54546A (fr) | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a | |
MA52486A (fr) | Pyridazinones utilisés en tant qu'inhibiteurs de parp7 | |
MA48994A (fr) | Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1 | |
MA51878A (fr) | Composés d'aminothiazole en tant qu'inhibiteurs de c-kit | |
MA44725A (fr) | Formulations d'un inhibiteur de lsd1 | |
MA47576A (fr) | Composés inhibiteurs d'oga bicyclique | |
MA52413A (fr) | Inhibiteurs de cd73 | |
MA51232A (fr) | Indane-amines utiles en tant qu'antagonistes de pd-l1 | |
MA51438A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1 | |
MA41551A (fr) | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 | |
DK3687994T3 (da) | Gadolinium-bærende pcta-baserede kontrastmidler | |
MA45377A (fr) | Composés hétérocycliques en tant qu'agents antibacteriens | |
MA48765A (fr) | Cyanopyrrolidines substituées par sulfonamide ayant une activité en tant qu'inhibiteurs de dub | |
MA52063A (fr) | Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique | |
MA51616A (fr) | Inhibiteurs d'adn-pk | |
MA43169A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma | |
MA52942A (fr) | Composés inhibiteurs d'oga | |
MA47460A (fr) | Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase | |
MA46242A (fr) | Composés inhibiteurs de bêta-lactamase | |
MA52939A (fr) | Composés inhibiteurs d'oga | |
MA42919A (fr) | Composés bicycliques utilisés en tant qu'inhibiteurs d'atx | |
MA42918A (fr) | Composés bicycliques utilisés en tant qu'inhibiteurs d'atx | |
MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
MA47420A (fr) | Composés inhibiteurs d'oga |